These strategies, such as immune checkpoint blockade and chimeric antigen receptor T cells (Pedroza-Gonzalez et al., 2011), mainly aim at reactivating tumor-infiltrating CD8+ cytotoxic T lymphocytes (CTLs) against late-stage metastatic cancers (Mellman et al., 2011). The gene discussed is CD8A; the disease is neoplasm.